Literature DB >> 21208978

Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.

Faye A H Cooles, Graham H Jackson, Geetha Menon, John D Isaacs.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21208978     DOI: 10.1093/rheumatology/keq429

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  3 in total

Review 1.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 2.  Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.

Authors:  Ilaria Pagnini; Antonio Vitale; Carlo Selmi; Rolando Cimaz; Luca Cantarini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 10.817

3.  Long-term efficacy of alemtuzumab in polymyositis.

Authors:  Tobias Ruck; Stefan Bittner; Tanja Kuhlmann; Heinz Wiendl; Sven G Meuth
Journal:  Rheumatology (Oxford)       Date:  2014-12-30       Impact factor: 7.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.